Pasithea Therapeutics Corporation has announced updated compensation arrangements for its executive officers and directors. Effective retroactively to January 1, 2025, Chief Executive Officer Dr. Tiago Reis Marques will receive a base salary increase to $533,000 with a target bonus set at 55% of his annual base salary. Chief Financial Officer Daniel Schneiderman's base salary will rise to $391,000, with a target bonus increased to 40% of his annual base salary. To conserve cash, the company amended its consulting agreement with Prof. Steinman, reducing payments from $25,000 per quarter to $1.00 per quarter. In recognition, Prof. Steinman was granted a one-time stock option award to purchase 200,000 shares at $0.715 per share, vesting fully after one year or upon a Change in Control. Additionally, Dr. Marques received options to purchase 493,341 shares, Mr. Schneiderman 317,266 shares, and certain employees a total of 352,266 shares, all at an exercise price of $0.715 per share. These options vest 33% after one year, with the remainder vesting quarterly over two years, or fully upon a Change in Control.